Anti-inflammatory Effect of Atorvastatin on Graft Donor Kidney
Anti-inflammatory Effect of Atorvastatin on Graft Donor Kidney Transplantation in Vivo
Renal Insufficiency is a priority disease in health system, which may require renal replacement therapy based on renal transplantation, which is considered as therapy of choice. During the procedure of renal transplantation, the graft could be damaged by ischemia-reperfusion which generates complications in its function.
Recently the anti-inflammatory and immunomodulatory effects of statins have been emphasized, which could be beneficial in renal transplantation.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Objective: Evaluate anti-inflammatory effect of atorvastatin on renal graft in living donor transplantation.
Material and methods: Controlled, double-blind clinical trial with posterior following for 12 months. Composed by 48 patients, randomized manner, realized at the Transplant Department of Western Medical Center, Mexican Institute of Social Security. Universe was patients accepted as kidney donors. Patients were randomized in two groups (study or control) the intervention was implemented 4 weeks before kidney transplant. Previous surgical procedure, in a blood sample, C-Reactive Protein (C-RP) and laboratory control were measured. During surgical procedure, a biopsy was obtained to measure IL-6 and tumoral necrosis factor alpha by immunohistochemistry. 24 hours after surgical procedure, 3 and 12 months of following, kidney function, complications and graft survival were registered. During surgical procedure, 3 months and 12 months of following, biopsies were obtain to performed histopathological analysis of scale of Banff
The statistical analysis was performed according to the nature of variables, for continuous data using measures of central tendency and dispersion and for the qualitative data with frequencies and percentages.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
Jalisco
-
Guadalajara, Jalisco, México, 44340
- Western Medical Center, Mexican Institute of Social Security
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Accepted as kidney donor
- Voluntary participation
- Informed consent accepted
- 85% fulfillment of atorvastatin treatment
Exclusion Criteria:
- Hypersensibility to Atorvastatin
- Smoking
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Atorvastatin
22 patients received oral atorvastatin 40 mg 1 time for day for 4 weeks
|
Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation.
Previous surgical procedure controls were performed
Outros nomes:
|
|
Comparador de Placebo: Placebo
22 patients received oral placebo 40 mg 1 time for day for 4 weeks
|
Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation.
Previous surgical procedure were performed
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
C-Reactive Protein evolution in donors
Prazo: Basal and 4 weeks later
|
C-Reactive Protein was measured when patients (donors) were accepted in the study and 4 weeks later.
The last blood sample was taken the day of surgical procedure.
|
Basal and 4 weeks later
|
|
Kidney graft rejection using scale of BANFF
Prazo: Basal, 3 months and 12 months
|
During surgical procedure and before organ transplantation, basal biopsy was obtain.
In the following at 3 and 12 months after kidney transplantation, were performed the other two biopsy.
Alterations between groups were registered.
|
Basal, 3 months and 12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Kidney function evolution after transplant
Prazo: 24 hours, 3 months and 12 months
|
In blood samples, after kidney transplantation, creatinine and urea were measured.
Differences in evolution and alteration between the 2 groups were registered
|
24 hours, 3 months and 12 months
|
|
Interleukin and tumor necrosis factor alpha.
Prazo: Basal
|
During surgical procedure and before organ transplantation, the biopsy was obtain to measure interleukin 6 and tumor necrosis factor alpha, observing alteration between groups.
|
Basal
|
|
Complications
Prazo: 24 hours, 3 months and 12 months
|
During surgical procedure, any kind of complication was registered, the same right after surgery and in the following.
|
24 hours, 3 months and 12 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Clotilde Fuentes-Orozco, PhD, Instituto Mexicano del Seguro Social
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2011-1301-78
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .